Last-resort radiation treatment offers hope for rare childhood and adult cancers
NCT ID NCT01850888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gave a radioactive drug called 131I-MIBG to 15 people with advanced nerve tumors (neuroblastoma or pheochromocytoma) that had stopped responding to standard treatments. The goal was to see if it could ease symptoms and shrink tumors, while tracking side effects. Participants received different doses based on their health and stem cell availability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to shrink rare adrenal tumors
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
- Supercharged immune cells take aim at childhood cancers
- New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
- Radioactive 'Smart Bomb' targets tough childhood cancer
- Engineered immune cells take aim at childhood cancer